merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>risks outweigh potential benefits</answer>
<question_number>2</question_number>
<answer>discourage participation in trials for better treatments</answer>
<question_number>3</question_number>
<answer>no correlation between removal and clinical response</answer>
<question_number>4</question_number>
<answer>increased perception of safety risks</answer>
<question_number>5</question_number>
<answer>patients can stop after amyloid is cleared</answer>
<question_number>6</question_number>
<answer>may discourage participation in trials for better treatments</answer>
<question_number>7</question_number>
<answer>patients can stop dosing after clearing amyloid</answer>
<question_number>8</question_number>
<answer>amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>intermediate tau levels declined more slowly</answer>